initi buy potenti
interest io asset nsclc rcc
crv advanc dev prgm adenosin io target
pursu sever biotechs/larg pharma lead asset like access
nich later-lin set nsclc rcc w/ resist checkpoint
inh though indic competit management emphas
advantag keep well-posit among io agent initi w/
buy pt
joint-book run manag crv secondari offer
show promis later-lin nsclc rcc antagonist
shown reason dcr nsclc rcc demonstr earli sign
efficaci pi/ib studi singl agent combo w/ atezolizumab pt
and/or favor attribut
incl clean safeti profil oral deliveri provid pot add-on therapi option
inh key upcom catalyst top-line data rcc expans cohort
late risk tie drop-off efficaci latest dcr single/
management focus strategi pursu approv rcc given robust
dcr rcc management amend pi/ib protocol convert studi rcc enrol
add pt healthier pt requir failur prior line incl tki
inh management plan meet w/ fda discuss pivot trial could initi
earli like rcc pursu registr may also consid
biomark pt select also viabl path forward nsclc
pib/ii studi atezo enrol collabor roch morpheu
pipelin provid option combo strategi target adenosin axi
crv key asset mab compel setup dual
blockad adenosin axi typic redund inhibit node
pathway preclin data support synergist effect target therefor
combo arm includ current enrol pi/ib studi also
evalu monotherapi combo w/ pembrolizumab nsclc rcc
solid tumor
pt dcf-base valu crv entir valu current ascrib
remain pipelin risk incl clinic mfr ing competit regulatori comm
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
approv rcc nsclc us
eu
posit feedback fda meet registr trial
design rcc enrol start earli
model us peak sale risk-adj eu peak sale
risk-adj rcc appli risk discount
model us peak sale risk-adj eu peak sale
risk-adjust nsclc appli risk
discount
retain upsid current model
valuat
rcc derisk posit expans
nsclc derisk posit pi/ib data
morpheu collabor roch price target
repres addit upsid
develop unsuccess rcc price
develop unsuccess nsclc price
late top-line data rcc expans cohort
fda meet discuss registr trial design cpi-
rcc
enrol dose expans cohort pi/ib trial
file ind/complet preclin studi
earli top-line data roch morpheu pi/ib trial cpi-
nsclc
earli initi pi trial t-cell lymphoma
solid tumor
initi piii registr trial rcc
page
pleas see import disclosur inform page report
corvu pharmaceut inc crv clinical-stag biotechnolog
compani focu develop immuno-oncolog io therapi
direct adenosin signal pathway there clear role
adenosin potent
immunosuppress factor within tumor
microenviron inhibit adenosin metabol emerg
potenti strategi improv tumor immun respons could enhanc
efficaci checkpoint inhibitor crv lead asset novel small
molecul inhibitor adenosin receptor critic
signal node pathway pi/ib trial collabor roch
evalu singl agent combin roch
inhibitor atezolizumab across sever solid tumor indic
shown promis activ non-smal cell lung cancer nsclc renal cell
carcinoma rcc monotherapi combin therapi along
clean safeti profil base preliminari result crv elect
expans mono combo nsclc rcc cohort includ
protocol amend convert studi trial rcc
patient manag plan initi enrol pivot piii trial
rcc presum focu therapi inhibitor provid
there favor fda feedback rcc registr studi could
underway earli develop nsclc continu
set roch morpheu program umbrella protocol
design rapidli advanc prospect io combo therapi crv second
asset monoclon antibodi direct enzym
respons gener extracellular adenosin follow solid
preclin data crv begun enrol pi/ib trial arm
monotherapi pembrolizumab lastli
crv itk inhibitor famili btk target imbruvica
preclin develop plan file ind enter
clinic see option number io strategi crv
pipelin keep competit among peer develop io asset
modifi cytokin ido inhibitor initi buy pt
compos
show respect outcom prior treatment histori
express taken consider there high
expect crv sinc first data eye
toward cross-trial comparison vs competitor io add-on therapi
inhibitor think mani investor discount efficaci given
limit partial respons pr skew toward stabl diseas sd
nsclc rcc howev import recal major
tough-to-treat case
resistant/refractori therapi nsclc rcc last
data cutoff well neg express nsclc rcc
sicker group patient measur well includ high
percentag advers prognost factor viscer metastas elev
lactat dehydrogenas anemia indic diseas furthermor
recent protocol amend heavili pre-treat patient
enrol rcc cohort includ upward three four prior
line therapi one rcc patient fail five line prior therapi
includ nivolumab experienc pr advantag
demonstr efficaci singl agent uniformli true io
agent investig add-on therapi inhibitor oral
formul potenti make attract competitor
page
pleas see import disclosur inform page report
dose iv taken togeth think profil remain compel
spite highli competit natur io therapeut landscap
there option combo strategi target adenosin
could help crv traction nsclc rcc there grow
interest adenosin pathway therapeut target solid tumor
evidenc sever biotech larg pharma compani develop
acquir program target adenosin receptor and/or within
landscap crv appear rel well-posit given
advanc program well strong second asset
resistant/refractori and/or patient nsclc rcc rcc
stronger two dataset howev combo cpi-
could prove underappreci regimen though target two
node signal pathway often consid redund there
substanti preclin data indic dual blockad
robust synergist effect anim tumor model arm
crv current enrol pi/ib trial could therefor promis combo
one watch first data
could nich
valu crv lead product advanc nsclc rcc estim
total world-wide opportun million risk-adjust
present assum us eu commerci carri corvu
nsclc assum market entri therapi us eu
estim us peak sale approxim million risk-adjust eu peak
sale approxim million risk-adjust assum discount rate
market rcc assum market entri treatment us
eu estim us peak sale approxim risk-adjust eu peak
sale approxim risk-adjust assum discount rate
model pi/ib develop treatment advanc nsclc
rcc preclin develop treatment itk-driven t-cell lymphoma
asset repres upsid estim arriv price target
base discount cash flow valuat model assum wacc
termin growth rate outstand share million exhibit
page
pleas see import disclosur inform page report
clinic failur compani
biotechnolog pharmaceut
develop treatment futur clinic failur on-going clinic trial may
impact estim
regulatori failur fda and/or ema may delay approv compani
investig target delay approv could lead chang estim price
commerci risk delay market entri chang reimburs and/or potenti
competit threat could lead us revis estim price target and/or rate
competit risk compani develop treatment variou stage
clinic develop compet compani clinical-stag asset
product candid superior therapeut profil approv
compani product marketplac even approv could advers impact
financ risk compani may need rais addit fund support sg
 activ
headquart
burlingam california corvu
pharmaceut inc crv clinical-stag biopharmaceut compani focus
develop commerci novel immuno-oncolog therapi span
small molecul antibodi focu adenosin pathway compani
lead asset oral antagonist adenosin receptor
identifi immun checkpoint current pib/ii develop
investig monotherapi combin therapi roch
checkpoint inhibitor atezolizumab tecentriq sever solid cancer includ
advanc nsclc rcc monoclon antibodi inhibit
product adenosin recent initi pi/ib trial itk inhibitor
block t-cell differenti current undergo ind-en studi
plan file ind initi pi trial earli compani complet
pipelin exhibit upcom catalyst exhibit depict follow
page
pleas see import disclosur inform page report
page
pleas see import disclosur inform page report
antagonist initi rcc expans cohort amend pi/ib data rcc expans cohortl meet discuss registr trial design data roch morpheu pib/ii trial nsclcearli registr trial mab initi pi/ib trial nsclc rcc solid dose expans cohort pi/ib itk inhibitor file ind/complet preclin studiesy pi trial t-cell lymphoma solid tumorsearli antagonistselect preclin develop crv
origin drug modul activ crv lead product cpr-
in-licens vernali plc cover februari
up-front fee aggreg mileston development regulatori commerci
mid-singl low-doubl digit tier royalti agreement vernali grant
exclus world-wide licens patent cover composit matter method use
project expir januari juli us expiri date
exclud term extens may grant interestingli
develop varieti neurolog condit wholli own vernali
develop improv upon safeti concern seen vipaden anoth
antagonist test vernali collabor yee hold
treatment parkinson diseas follow discontinu vipaden due safeti
signal vernali conduct sever trial includ two pi studi healthi
volunt one pib studi patient attention-deficit hyperact disord
adhd oral dose mg/day total patient dose
across three studi patient receiv singl dose patient treat
qd bid two week result sizabl amount safeti data
avail crv in-licens asset well-toler
seriou advers event commonli report toxic minor gi
disturb minim transient elev blood pressur
preclin work valid potenti io agent anti-
tumor efficaci cell-bas assay demonstr abil disrupt
downstream signal treatment t-cell stabl adenosin analogu
n-ethylcarboxamid adenosin neca result burst camp product
confirm activ t-cell pre-treat neca
incub complet inhibit camp product observ
concentr um drug inhibit occur nm anoth test
mechan t-cell expos neca alon neca plu assess
product inflammatori cytokin ifn-i stimul neca
activ led decreas level ifn-i level
almost complet rescu addit um data valid
mechan indic drug restor t-cell activ cytokin secret
competit inhibit
understand whether mechan translat efficaci anim model mice
graft colon cancer cell display limit respons
inhibit mice treat day vehicl control inhibitor alon
alon combin inhibitor day follow
treatment single-ag inhibitor modest decreas volum
xenograft tumor mean compar control mean similarli
monotherapi yield small reduct tumor burden mean
howev inhibitor plu combo almost complet suppress tumor
growth day mean exhibit left panel importantli mice
receiv combo therapi show cr rate compar
alon alon exhibit right panel similar experi
compar alon combo either inhibitor gemcitabin
differ colon adenocarcinoma cell line yield compar result
show synergi combo therapi chemotherapi
page
pleas see import disclosur inform page report
exhibit preclin data mous model colon adenocarcinoma
assess pi/ib trial enrol sever advanc cancer
januari crv initi enrol open-label pi/ib trial expans
cohort design patient advanc cancer studi assess
monotherapi combin therapi atezolizumab collabor
agreement roch patient permit receiv prior
therapi though select made express level patient
requir progress diseas date patient enrol
site us canada australia first phase trial test
singl agent cohort random patient three cohort
investig monotherapi differ dose schedul mg bid
mg qd mg bid fourth cohort investig alon
mg bid follow combo fix dose atezolizumab
mg exhibit cohort treatment adher cycl
diseas progress toxic occur first phase complet novemb
enrol patient treat specifi per protocol
one dropout prior treatment base safeti pharmacodynam find cpi-
dose mg bid select monotherapi combo therapi
second pib phase trial enrol disease-specif cohort patient
five cohort receiv monotherapi five receiv
combo atezolizumab tumor histolog select inclus
nsclc rcc melanoma tnbc categori compris bladder cancer
prostat cancer colorect cancer high mutat rate design allow
expans cohort addit patient total patient there
evid anti-tumor activ defin complet partial respons
diseas stabil recist criteria greater three month least one patient
activ note five patient cohort expand
addit patient total patient exhibit given design initi result
nsclc rcc cohort met criterion first expans patient
rcc cohort also met criterion second expans patient
page
pleas see import disclosur inform page report
aacr data show activ safeti singl agent
combin therapi crv present three key interim
data set nation oncolog meet last year first occur
april first interim data pi/ib trial report efficaci safeti
evalu patient enrol distribut follow tnbc
nsclc melanoma rcc median age year old
patient fail prior therapi receiv median two prior therapi
rang resistant/refractori inhibitor furthermor
patient viscer metastas includ metastas liver brain
importantli show rel clean toxic profil singl agent
ad atezolizumab common monotherapi nausea
pruritu abdomin pain rash diarrhea fever decreas appetit fatigu
fever grade note alon given
togeth atezolizumab three seriou report two patient first
patient experienc grade autoimmun haemolyt anemia second patient
grade asept autoimmun enceph grade thrombocytopenia howev
autoimmun resolv treatment discontinu known side
effect checkpoint inhibitor therapi
efficaci patient display degre tumor regress
previous treat resistant/refractori three
treat alon one nsclc patient one colorect cancer patient
treat combo therapi remain patient saw minor respons
tumor volum regress includ seven patient receiv alon
four patient receiv combo therapi limit number pr trigger crv sell-off
given heighten expect bake around
readout stock run prior month howev import note
pi/ib trial enrol gener sicker patient need novel therapeut option
resistant/refractori well sever hard-to-treat tumor type
tnbc like lower respons rate overal popul
anoth measur efficaci dcr partial/minor respons plu stabl diseas
patient treat monotherapi treat
atezolizumab median follow-up week intriguingli
analyz prior therapi higher dcr seen among
resistant/refractori patient compar nave patient among tumor
type nsclc rcc cohort show best signal activ nsclc
dcr monotherapi combo therapi
rcc dcr monotherapi combo therapi
page
pleas see import disclosur inform page report
given promis find tumor type expans cohort
greenlight singl combo trial arm nsclc rcc
asco put spotlight nsclc rcc next key data cpi-
came june crv present addit data
monotherapi combo therapi cohort nsclc rcc time
data cutoff nsclc patient resistant/refractori inhibitor
use fda-approv assay cutoff
express median number prior therapi among nsclc patient two
evalu nsclc patient two experienc pr one confirm
on-going six month patient resistant/refractori second
pr unconfirm also occur patient character
resistant/refractori addit nsclc patient stabl diseas four
stabl diseas greater month rcc patient found anti-
refractori rcc cohort median three
prior line therapi among evalu patient two confirm pr one
treat monotherapi fail prior therapi
anoth rcc patient stabl diseas six stabl diseas period
exceed six month data report limit number pr high
proport resist neg among nsclc rcc
identifi rcc focu registr studi
highlight adenosin axi biomark third dataset consist updat
rcc cohort novemb time data cutoff rcc
patient resistant/refractori inhibitor wherea neg
use cutoff express median number prior therapi remain three
vast major patient show clear cell histolog case
papillari type overal sicker popul demonstr poor
prognost featur viscer metastas hepat metastas anemia
elev serum lactat dehydrogenas evalu
patient receiv alon receiv
atezolizumab pr one confirm one unconfirm monotherapi
two confirm combo therapi singl agent respons occur anti-
resistant/refractori patient dcr monotherapi
atezolizumab safeti profil remain rel clean
similar previous report across total patient account
mono combo arm grade occur includ fatigu nausea
pruritu pyrexia decreas appetit diarrhea anemia monotherapi
one patient experienc high-grad nausea/vomiting/diarrhea
part present crv show adenosin pathway biomark
increas patient patient receiv least
three month prior therapi show largest increas adenosin
pathway biomark express compar nave patient receiv less
three month therapi understand dcr vari biomark level patient across
tumor type tissu avail biomark assess classifi either
neg posit express dcr
classifi neg vs classifi posit
express dcr classifi neg vs classifi
posit interestingli dcr remain low double-
page
pleas see import disclosur inform page report
neg patient significantli rose double-posit
patient also exce dcr seen single-posit patient
addit posit found correl tumor
regress pr show highest correl doubl posit exhibit
lastli biopsi tumor post-treat monotherapi show
increas t-cell infiltr express marker activ
granzym granzym
exhibit correl tumor progression/regress adenosin axi
morpheu programexpand roch collabor drive develop
nsclc may crv expand exist clinic collabor roch
initi pib/ii trial combin atezolizumab nsclc
studi random control trial began enrol septemb
target enrol patient previous fail platinum-bas chemotherapi
regimen and/or therapi compar arm docetaxel
approv treatment nsclc trial part morpheu program
clinic trial platform develop roch enabl rapid go/no-go decis
acceler develop promis io combo therapi briefli program leverag
umbrella protocol across
control/compar arm possibl enrol patient categor use
biomark permit enter differ combin arm diseas progress
latest interim data step last data cutoff jan
nsclc patient enrol resistant/refractori anti-pd-
receiv two median line prior therapi
exhibit left panel also rcc patient enrol
resistant/refractori receiv three
median line prior therapi exhibit right panel
standard-of-car
page
pleas see import disclosur inform page report
exhibit nsclc rcc cohort characterist
nsclc latest dcr single-ag
atezolizumab six patient remain treatment month two patient
reach durat one year exhibit rcc latest dcr single-
agent atezolizumab patient remain treatment
six month four patient reach durat one year exhibit notabl
six pr record includ five still on-going rang
month treatment rcc patient experienc pr single-ag
includ heavili pre-treat patient fail five prior regimen pazopanib
exhibit nsclc tumor respons durat studi
page
pleas see import disclosur inform page report
exhibit rcc tumor respons durat studi
given roch morpheu program advanc nsclc indic crv
decid put resourc behind rcc amend current pi/ib trial
convert trial rcc combo cohort addit patient
enrol singl arm test atezolizumab primari endpoint
respons rate importantli amend specifi rcc patient fail
two prior line therapi must includ tyrosin kinas
inhibitor tki therapi previous patient fail five prior
therapi elig enrol manag initi enrol
amend protocol expect hold meet fda
regulatori path forward rcc provid there favor feedback agenc
pivot piii trial rcc could underway like registr studi
would enrol rcc patient fail tki therapi align
popul amend pi/ib protocol also possibl enrol
criteria screen adenosin axi biomark express order
despit io advanc there remain unmet need patient fail
therapi regard advanc nsclc there grow number
patient respond plethora avail checkpoint inhibitor even
highli select subgroup current standard care nsclc patient fail anti-
therapi set docetaxel-bas regimen novel agent
need address popul regard advanc rcc fda recent approv
combo nivolumab plu ipilimumab use therapi practice-
chang advanc that like shift usag tki mtor inhibitor
addit nivolumab monotherapi alreadi establish go-to agent
set despit traction gain io agent mani rcc patient fail achiev
object respons standard-of-car exist resistant/refractori
patient backdrop think well-posit address
unmet need given efficaci shown resistant/refractori
patient well monotherapi
combin regimen induc tumor regress former rariti among
recent io agent latter suggest synergi checkpoint inhibit
page
pleas see import disclosur inform page report
howev therapeut space remain highli competit highlight sever io
asset similar development stage could challeng role add-
therapi checkpoint inhibitor nsclc and/or rcc
armo asset look compel multipl solid tumor type there
resurg interest cytokin io agent combin checkpoint
inhibitor one high-profil asset armo bioscienc armo buy pegyl il-
pegilodecakin advanc pivot piii studi pancreat
cancer sequoia piib studi nsclc there addit earli
efficaci signal pi/ii trial rcc melanoma colorect cancer also
encourag interestingli thought immunosuppress cytokin
base basic scienc research demonstr abil inhibit antigen-
present cell dendrit cell macrophag stimul t-cell
howev there also data show contribut activ expans
increas infiltr cytotox t-cell compani data packag
compel enough prompt takeout cover ian hillik
buy purchas armo all-cash deal valu billion
contend nsclc show single-ag combo
efficaci nsclc armo report impress data pi trial
monotherapi combin pembrolizumab nivolumab
octob cutoff monotherapi arm receiv median
three prior line therapi wherea pembrolizumab nivolumab combo
arm saw two prior line therapi report either monotherapi
combo therapi arm respect orr dcr seen patient
treat singl agent orr dcr mpf
month mo month landmark one-year surviv rate
receiv combo pembrolizumab nivolumab orr/dcr
respect exhibit given rel small number
enrol patient especi monotherapi pembrolizumab combo arm
discount respons rate like appropri dcr single-
combo therapi still compar favor crv recal dcr
singl combo therapi nsclc respect furthermor mo
yet reach either cohort median follow-up month
pembrolizumab month nivolumab posit sign
given mo pembrolizumab previous treat nsclc patient
report month
exhibit efficaci monotherapi combin therapi nsclc
subject avail test neg subject avail test neg nr reach
clinic trial progress number octob median follow-up month rang nr reach clinic trial progress number
octob median follow-up month rang
page
pleas see import disclosur inform page report
piib cypress trial provid data read-through
competit nsclc armo initi cypress piib clinic
develop program includ two random control trial
evalu high/low express nsclc respect
plu pembrolizumab vs pembrolizumab alon assess
therapi patient high express
plu nivolumab alon assess therapi patient low
neg express armo enrol first patient march
enrol expect initi first preliminari
result expect would key point comparison vs roche/crv
morpheu pi/ib trial plu atezolizumab focu would nsclc
market like compet close add-
therapi inhibitor
path rcc elucid rcc there also compel
data pi trial monotherapi combin
pembrolizumab nivolumab octob cutoff howev
compani yet disclos develop program indic
monotherapi arm receiv median three prior line therapi
pembrolizumab nivolumab arm saw median two one prior line therapi
respect patient treat singl agent cr orr
dcr patient treat combo plu nivolumab
cr orr dcr patient treat combo
plu pembrolizumab cr orr dcr
albeit small sampl eight patient exhibit
one could discount respons rate howev face valu perform
rcc competit crv recal dcr
singl combo therapi rcc respect monotherapi mpf
month mo yet reach median follow-up time
month nivolumab mpf mo yet reach
median follow-up time month point comparison nivolumab
monotherapi trial rcc report averag mpf month averag
mo month mo reach possibl
inhibitor provid better surviv benefit compar nivolumab monotherapi
sinc could indic os armo appear evalu option yet
announc develop plan rcc rcc repres
logic entri point would directli compet thu far appear
crv lean toward entri rcc given amend pi/ib protocol
specifi prior regimen includ therapi tki
exhibit efficaci monotherapi combin therapi rcc
clinic trial progress number octob median follow-up month rang clinic trial progress number octob
median follow-up month rang partial respons reduct measur diseas studi motzer et
al nejm nivolumab rcc
page
pleas see import disclosur inform page report
nktr asset bring old io therapi back recal paid
billion cash februari licens part right
cover david steinberg buy pegyl approv late
trade name proleukin aldesleukin one
immunotherapi use rcc metastat melanoma proleukin incorpor
sever modif nativ molecul includ delet n-termin
alanin substitut serin cystein amino acid posit still proleukin
short half-lif minut requir frequent dose everi eight
hour dose per cycl two cycl monthli importantli drug suffer
well-known toxic issu requir black box warn label major
concern stem vascular leak syndrom lead hypotens cardiac
arrhythmia renal impair mental statu chang addit there
infecti concern sinc known impair neutrophil function
biolog prodrug consist bound six cleavabl polyethylen glycol
chain serv agonist receptor beta chain drug prevent
associ receptor alpha subunit preferenti drive format so-
call intermedi affin receptor predispos prolifer effector
t-cell furthermor absenc bind high-affin receptor
unabl form thu expans immunosuppress treg prevent
preclin studi show mean ratio infiltr t-cell
t-cell within tumor microenviron support state mechan
action
anoth competit combo option nsclc
rcc pi/ii dose escal trial enrol io treatment-nav patient
distribut patient melanoma patient nsclc patient
rcc note assess sole combin therapi
nivolumab studi without monotherapi arm orr
dcr report nsclc across combin wherea orr
dcr patient specif exhibit five
nsclc patient test rcc orr dcr
report patient receiv post-baselin scan also
calcul orr dcr stringent
criterion post-baselin scan exhibit group express
statu rcc patient saw
respons among whose tumor evalu express
plan major updat data june howev
manag provid occasion increment updat recent
given earn call orr rcc improv vs previou
per manag respons rate increas time tumor
type well current there orr seen patient
relaps discontinu therapi note nivolumab show
numer higher orr nsclc rcc compar armo
pembrolizumab nivolumab armo enrol sicker patient saw median
two prior line therapi vs line therapi howev there often
drop respons rate move one line therapi next make
data armo asset quit compar adjust appli
exhibit think remain highli
competit cytokin add-on option therapi beyond asco
pack clinic develop program enrol across
dose expans cohort pi propel studi pembrolizumab atezolizumab
page
pleas see import disclosur inform page report
